New trial site, the University of Pittsburgh Medical Center, joins GID BIO’s pivotal Phase III trial

peter rubin

Peter Rubin, MD, MBA, FACS, Endowed Professor and Chair of Plastic Surgery at the Center for Innovation in Restorative Medicine at UPMC and the University of Pittsburgh joins as GID BIO’s latest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. 

“This is a very important study being done in a rigorous, randomized, controlled manner with the potential to develop Level 1 evidence in support of cell therapy for musculoskeletal treatments. I have been studying cell therapy in the laboratory for many years and our team is excited about participating in this clinical trial,” noted Dr. Rubin. 

His team joins seven other trial sites across the country including Wake Forest School of Medicine, OrthoCarolina, and AdventHealth Orlando led by Neil Sparks, DO, MS, Claude T. Moorman, III, MD, and Tariq Awan, DO, respectively.

For more information about the trial, visit clinicaltrials.gov.

Our cell therapy is not approved by the FDA for sale or use in the US.